Perrigo | PRGO - Selling And Administration Expenses


Perrigo reported $267.3M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Abbott USD 3.27B 138M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Corcept Therapeutics USD 128.04M 13.3M Mar/2026
Dr.Reddys Laboratories INR 26.92B 482M Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
J&J USD 6.03B 719M Mar/2026
Merck USD 2.67B 180M Mar/2026
Nestle CHF 12.46B 267M Dec/2025
Pacira USD 83.88M 7.99M Mar/2026
Perrigo USD 267.3M 11.4M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Phibro Animal Health USD 78.32M 10.24M Dec/2025
Prestige Brands USD 30.28M 606K Mar/2026
Sanofi EUR 2.33B 419M Mar/2026
Supernus Pharmaceuticals USD 118.23M 4.16M Mar/2026
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026
Xeris Pharmaceuticals USD 42.64M 3.82M Dec/2025
Zoetis USD 588M 31M Mar/2026